Business
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mo
About this update from Genprex, Inc.
[{"type":"text","content":"Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifically addressing Type 2 diabetes (T2D).","length":654,"tagName":"p"},{"type":"image","alt":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xA37qCr88_2_J9WjJLKhZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This past year was instrumental for Genprex as we expanded our preclinical research beyond Type 1 diabetes and into Type 2 diabetes, marking the achievement of a significant milestone in our diabetes gene therapy program, including the successful initiation of preclinical research in Type 2 diabetic animal models," said Ryan Confer, President and Chief Executive Officer. "Furthermore, we have successfully executed our strategic plan to transfer production of GPX-002 to an experienced Contract Develop...